Range Low Price High Price Comment
30 days $2.07 $3.69 Tuesday, 30th Apr 2024 CASI stock ended at $2.35. This is 0.598% more than the trading day before Monday, 29th Apr 2024. During the day the stock fluctuated 7.52% from a day low at $2.26 to a day high of $2.43.
90 days $2.07 $7.15
52 weeks $1.86 $8.48

Historical CASI Pharmaceuticals prices

Date Open High Low Close Volume
Feb 02, 2016 $0.93 $1.00 $0.86 $0.89 34 900
Feb 01, 2016 $1.06 $1.15 $0.86 $0.92 98 300
Jan 29, 2016 $1.19 $1.19 $1.08 $1.08 31 400
Jan 28, 2016 $1.13 $1.18 $1.11 $1.13 42 600
Jan 27, 2016 $1.04 $1.18 $1.04 $1.13 55 200
Jan 26, 2016 $1.13 $1.13 $0.95 $1.03 19 000
Jan 25, 2016 $0.86 $1.13 $0.86 $1.09 92 200
Jan 22, 2016 $0.700 $0.90 $0.700 $0.83 64 800
Jan 21, 2016 $0.710 $0.740 $0.710 $0.710 8 100
Jan 20, 2016 $0.720 $0.750 $0.690 $0.740 34 200
Jan 19, 2016 $0.680 $0.770 $0.650 $0.710 104 200
Jan 15, 2016 $0.750 $0.80 $0.700 $0.720 17 100
Jan 14, 2016 $0.700 $0.90 $0.650 $0.780 80 500
Jan 13, 2016 $0.87 $0.92 $0.580 $0.680 119 700
Jan 12, 2016 $0.89 $0.98 $0.89 $0.90 6 600
Jan 11, 2016 $0.90 $0.96 $0.85 $0.92 50 100
Jan 08, 2016 $0.94 $0.94 $0.90 $0.90 23 100
Jan 07, 2016 $0.91 $0.95 $0.90 $0.90 31 600
Jan 06, 2016 $0.96 $0.96 $0.94 $0.94 5 200
Jan 05, 2016 $0.98 $1.00 $0.94 $0.94 6 000
Click to get the best stock tips daily for free!

About CASI Pharmaceuticals

CASI Pharmaceuticals CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T inve... CASI Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT